2016


To access this material please log in or register

Register Authorize
2016/№1

Cardiorenal syndrome in intensive care

Vatutin N. T.1, Taradin G. G.1, Kolesnikov V. S.2, Taratorina A. A.2, Zinkovich M. I.1
1 – “M. Gorky Donetsk National Medical University” of the Ukraine Ministry of Health Care, Prospekt Iljicha 16, Donetsk 83003, Ukraine
2 – State Institution, “V. K. Gusak Institute of Urgent and Reconstructive Surgery of the Ukrainian National Academy of Medical Sciences”, Leninskij Prospekt 47, Donetsk 83045, Ukraine

Keywords: heart failure, cardiorenal syndrome, diagnostics, treatment, intensive care

DOI: 10.18087/rhfj.2016.1.2130

The review presents current concepts on cardiorenal syndrome (CRS), including its prevalence, RFs, pathogenesis, and clinical manifestations. The authors provide classification, diagnostic criteria, therapeutic and preventive approaches, and own data on CRS prevalence in elective transcutaneous coronary interventions (TCI). Special attention is paid to acute manifestations of CRS and treatment in intensive care units.
  1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012 Jul;33 (14):1787–847.
  2. Cruz DN, Bagshaw SM. Heart-kidney interaction: epidemiology of cardiorenal syndromes. Int J Nephrol. 2010 Dec 29;2011:351291.
  3. Heywood JT, Fonarow GC, Constanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007 Aug;13 (6):422–30.
  4. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007 Oct;13 (8):599–608.
  5. Breidthardt T, Socrates T, Noveanu M, Klima T, Heinisch C, Reichlin T et al. Effect and clinical prediction of worsening renal function in acute decompensated heart failure. Am J Cardiol. 2011 Mar 1;107 (5):730–5.
  6. Carubelli V, Metra M, Lombardi C, Bettari L, Bugatti S, Lazzarini V, Dei Cas L. Renal dysfunction in acute heart failure: epidemiology, mechanisms and assessment. Heart Fail Rev. 2012 Mar;17 (2):271–82.
  7. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006 May 16;47 (10):1987–96.
  8. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006 Feb 7;113 (5):671–8.
  9. Manolis AS, Papadimitriou P, Manolis TA, Apostolou T. Cardiorenal syndrome: a glimpse into some intricate interactions. Hospital chronicles. 2013;8 (1):3–15.
  10. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010 Mar;31 (6):703–11.
  11. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. JAMA. 1996 May 15;275 (19):1489–94.
  12. White LE, Hassoun HT. Inflammatory mechanisms of organ crosstalk during ischemic acute kidney injury. Int J Nephrol. 2012;2012:505197.
  13. Yap SC, Lee HT. Acute kidney injury and extrarenal organ dysfunction: new concepts and experimental evidence. Anesthesiology. 2012 May;116 (5):1139–48.
  14. Clementi A, Virzì GM, Brocca A, de Cal M, Pastori S, Clementi M et al. Advances in the pathogenesis of cardiorenal syndrome type 3. Oxid Med Cell Longev. 2015;2015:148082.
  15. Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am Heart J. 2005 Feb;149 (2):209–16.
  16. McAlister FA, Ezekowtiz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation. 2004 Mar 2;109 (8):1004–9.
  17. Shah BN, Greaves K. The cardiorenal syndrome: a review. Int J Nephrol. 2010 Dec 28;2011:920195.
  18. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006 Jul;17 (7):2034–47.
  19. Latchamsetty R, Fang J, Kline-Rogers E, Mukherjee D, Otten RF, LaBounty TM et al. Prognostic value of transient and sustained increase in in-hospital creatinine on outcomes of patients admitted with acute coronary syndrome. Am J Cardiol. 2007 Apr 1;99 (7):939–42.
  20. Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol. 2006 Oct;17 (10):2886–91.
  21. Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol. 2006 Jan;1 (1):8–18.
  22. Дзяк ГВ, Каплан ПА. Кардиоренальный синдром: патофизиология, классификация, подходы к лечению. Почки 2012;1:9–19 [Dzyak GV, Kaplan PA. Kardiorenal`ny`j sindrom: patofiziologiya, klassifikacziya, podxody` k lecheniyu. Pochki 2012;1:9–19].
  23. Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J. 2006 May;27 (10):1216–22.
  24. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol. 2007 Aug 21;50 (8):768–77.
  25. Roghi A, Savonitto S, Cavallini C, Arraiz G, Angoli L, Castriota F et al. Impact of acute renal failure following percutaneous coronary intervention on long-term mortality. J Cardiovasc Med (Hagerstown). 2008 Apr;9 (4):375–81.
  26. Lassnigg A, Schmid ER, Hiesmayr M, Falk C, Druml W, Bauer P, Schmidlin D. Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure? Crit Care Med. 2008 Apr;36 (4):1129–37.
  27. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: Guyton revisited. Eur Heart J. 2005 Jan;26 (1):11–7.
  28. Cruz DN. Cardiorenal syndrome in critical care: the acute cardiorenal and renocardiac syndromes. Adv Chronic Kidney Dis. 2013 Jan;20 (1):56–66.
  29. Jackson G, Gibbs CR, Davies MK, Lip GY. ABC of heart failure. Pathophysiology. BMJ. 2000 Jan 15;320 (7228):167–70.
  30. Aspromonte N, Cruz DN, Valle R, Bonello M, Tubaro M, Gambaro G et al. Metabolic and toxicological considerations for diuretic therapy in patients with acute heart failure. Expert Opin Drug Metab Toxicol. 2011 Sep;7 (9):1049–63.
  31. Aspromonte N, Cruz DN, Valle R, Ronco C. Management and monitoring of haemodynamic complications in acute heart failure. Heart Fail Rev. 2011 Nov;16 (6):575–81.
  32. Ellison DH. Diuretic therapy and resistance in congestive heart fai­lure. Cardiology. 2001;96 (3-4):132–43.
  33. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006 Sep 18;98 (6A): 14K-20K.
  34. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008 Apr 15;51 (15):1419–28.
  35. Liu Y, Chen SQ, Duan CY, Tan N, Chen JY, Zhou YL et al. Contrast volume-to-creatinine clearance ratio predicts the risk of contrast-induced nephropathy after percutaneous coronary intervention in patients with reduced ejection fraction. Angiology. 2015 Aug;66 (7):625–30.
  36. Lee DW, Faubel S, Edelstein CL. Cytokines in acute kidney injury (AKI). Clin Nephrol. 2011 Sep;76 (3):165–73.
  37. Havasi A, Borkan SC. Apoptosis and acute kidney injury. Kidney Int. 2011 Jul;80 (1):29–40.
  38. Virzi GM, Torregrossa R, Cruz DN, Chionh CY, de Cal M, Soni SS et al. Cardiorenal syndrome type1 may be immunologically mediated: a pilot evaluation of monocyte apoptosis. Cardiorenal Med. 2012 Feb;2 (1):33–42.
  39. Virzi GM, Clementi A, Brocca A, Cruz DN, de Cal M, Vescovo G et al. The hemodynamic and nonhemodynamic crosstalk in cardiorenal syndrome type 1. Cardiorenal Med. 2014 Aug;4 (2):103–12.
  40. Chuasuwan A, Kellum JA. Cardio-renal syndrome type 3: epidemiology, pathophysiology, and treatment. Semin Nephrol. 2012 Jan;32 (1):31–9.
  41. Kinsey GR, Li L, Okusa MD. Inflammation in acute kidney injury. Nephron Exp Nephrol. 2008;109 (4):e102–7.
  42. Визир ВА, Березин АЕ. Кардиоренальный синдром. Артериальная гипертензия. 2011; 2 (16): 100–9 [Vizir VA, Berezin AE. Kardiorenal`ny`j sindrom. Arterial`naya gipertenziya. 2011; 2 (16): 100–9].
  43. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008 Nov 4;52 (19):1527–39.
  44. Choudhary R, Gopal D, Kipper BA, De La Parra Landa A, Aramin H, Lee E et al. Cardiorenal biomarkers in acute heart failure. J Geriatr Cardiol. 2012 Sep;9 (3):292–304.
  45. Damman K, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL. Current and novel renal biomarkers in heart failure. Heart Fail Rev. 2012 Mar;17 (2):241–50.
  46. De Geus HRH, Betjes MG, Bakker J. Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges. Clin Kidney J. 2012 Apr;5 (2):102–108.
  47. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002 Jul;62 (1):237–44.
  48. Liangos MC, Perianayagam VS. Urinary N-acetyl-β-(D)-gluco­saminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007 Mar;18 (3):904–12.
  49. Sheira G, Noreldin N, Tamer A, Saad M. Urinary biomarker N-acetyl-β-D-gluco­saminidase can predict severity of renal damage in diabetic nephropathy J Diabet Metab Disord. 2015;14 (4):1–5.
  50. Needham DM, Shufelt KA, Tomlinson G, Scholey JW, Newton GE. Troponin I and T levels in renal failure patients without acute coronary syndrome: a systematic review of the literature. Can J Cardiol. 2004 Oct;20 (12):1212–8.
  51. Abbas NA, Jhon RI, Webb MC, Kempson ME, Potter AN, Price CP et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. Clin Chem. 2005 Nov;51 (11):2059–66.
  52. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008 May 15;358 (20):2148–59.
  53. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009 Feb 17;53 (7):589–96.
  54. House AA, Haapio М, Lassus J, Bellomo R, Ronco C. Phar­maco­logical management of cardiorenal syndromes. Int J Nephrol. 2011;2011:630809 [House AA, Haapio M, Lassus J, Bellomo R, Ronco C. Pharmacological management of cardiorenal syn­dromes. Int J Nephrol. 2011;2011:630809].
  55. De Vecchis R, Baldi C. Cardiorenal syndrome type 2: from diagnosis to optimal management. Ther Clin Risk Manag. 2014 Nov 12;10:949–61.
  56. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999 Sep 21;100 (12):1311–5.
  57. Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart fai­lure. Cochrane Database Syst Rev. 2005 Jul 20;3: CD003178.
  58. Shah RV, Givertz MM. Managing acute renal failure in patients with acute decompensated heart failure: the cardiorenal syndrome. Curr Heart Fail Rep. 2009 Sep;6 (3):176–81.
  59. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 3;364 (9):797–805.
  60. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007 Feb 13;49 (6):675–83.
  61. Heywood JT. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev. 2004 Jul;9 (3):195–201.
  62. den Uil CA, Lagrand WK, Valk SD, Spronk PE, Simoons ML. Management of cardiogenic shock: focus on tissue perfusion. Curr Probl Cardiol. 2009 Aug;34 (8):330–49.
  63. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008 Oct;10 (10):933–89.
  64. Koniari K, Nikolaou M, Paraskevaidis I, Parissis J. Therapeutic options for the management of the cardiorenal syndrome. Int J Nephrol. 2010 Dec 15;2011:194910.
  65. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012 Jul;33 (14):1787–847.
  66. Yilmaz MB, Yalta K, Yontar C, Karadas F, Erdem A, Turgut OO et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther. 2007 Dec;21 (6):431–5.
  67. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007 May 2;297 (17):1883–91.
  68. Reichert S, Ignaszewski A. Molecular and physiological effects of nesiritide. Can J Cardiol. 2008 Jul;24 (Suppl B): 15B-8B.
  69. Sackner-Bernstein J, Skopicki H, Aaronson K. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005 Mar 29;111 (12):1487–91.
  70. Givertz M, Massie BM, Fields TK, Pearson LL, Dittrich HC. The effects of KW-3902, an adenosine A1‑receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol. 2007 Oct 16;50 (16):1551–60.
  71. Bagshaw SM, Cruz DN. Fluid overload as a biomarker of heart failure and acute kidney injury. Contrib Nephrol. 2010;164:54–68
Vatutin N. T., Taradin G. G., Kolesnikov V. S., Taratorina A. A., Zinkovich M. I. Cardiorenal syndrome in intensive care. Russian Heart Failure Journal. 2016;17 (1):47–55

To access this material please log in or register

Register Authorize
Ru En